Exploring the microbiome in patients with cutaneous T cell lymphoma
Official title: Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Run by Northwestern University · NCT03932279 · Data updated 2026-11-12
This study looks at the gut bacteria of people with cutaneous T cell lymphoma to see how it compares to healthy individuals and if it can help us understand the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 89 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Northwestern University Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | January 30, 2019 |
| Main results expected | February 28, 2028 |
| Study ends | August 31, 2028 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT03932279 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18-89 with cutaneous T cell lymphoma at various stages, as well as individuals with related skin conditions and healthy controls.
✕Probably not a fit
Patients outside the age range of 18-89 or those with conditions not specified in the eligibility criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the microbiome of patients diagnosed with cutaneous T cell lymphoma and compare it to that of age and sex-matched healthy controls. The study will include various groups of patients with different stages of cutaneous T cell lymphoma, as well as individuals with related skin conditions and healthy participants. By analyzing the microbiome, researchers hope to uncover potential differences that could provide insights into the disease's pathology and treatment.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the microbiome's role in cutaneous T cell lymphoma, potentially leading to new therapeutic strategies.
How similar studies have gone: While the specific approach of characterizing the microbiome in cutaneous T cell lymphoma is novel, similar studies in other cancers have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma * Group 2: Patients with stage IIB and above cutaneous T cell lymphoma * Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma * Group 4: Patients with plaque psoriasis with BSA\>5% on routine phototherapy per standard of care * Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath therapy per standard of care * Group 6: Healthy individuals without the above skin conditions, similar age and sex distribution to the patients with cutaneous T cell lymphoma * All Groups: subjects who are age 18-89 years of age at time of enrollment * All Groups: Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443). Exclusion Criteria: * All Groups: Subjects who are younger than 18 years of age or older than 90 years of age * All Groups: Subjects who are unable to give consent * Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to systemic antibiotics * We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
Where it's running
-
Northwestern University
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Alan Zhou, MD — Northwestern University
- Study coordinator: Dermatology CTU
- Email: NUderm-research@northwestern.edu
- Phone: 312-503-5944
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma
This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.
-
Ropeginterferon treatment for cutaneous T‑cell lymphoma
This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.
-
Personalized exercise and nutrition program to reduce cancer-related fatigue
This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).
-
Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas
This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.
-
Tofacitinib cream for treating early-stage Cutaneous T-cell Lymphoma
This study is testing if a new cream can help people with early-stage Cutaneous T-cell Lymphoma feel better and improve their skin after 12 weeks of treatment.
-
Systemic treatments for cutaneous T‑cell lymphoma
This project looks at how different systemic treatments are used in adults with cutaneous T‑cell lymphoma to see which approaches are linked to longer disease control in routine care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.